IMS 2022 | Induction & consolidation therapy in newly diagnosed multiple myeloma
Luciano Costa
• 26 Aug 2022
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on optimal induction and consolidation therapy in patients with newly diagnosed multiple myeloma (NDMM). Dr Costa explains that several randomized trials have demonstrated that triplets, and later quadruplets consisting of a proteasome inhibitor (PI), an immunomodulatory agent (IMid), an anti-CD38 monoclonal antibody, and dexamethasone induce a deep sustained response in this patient population. Dr Costa further comments on consolidation therapy, highlighting the need to better define treatment depending on a patient’s baseline disease risk and depth of response. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
